海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录

Core Viewpoint - Haichuang Pharmaceutical (688302.SH) announced that its self-developed drug, Deuteroenzalutamide soft capsule, has been included in the National Medical Insurance Drug List after negotiations, effective from January 1, 2026 [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security published the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 [1] - Deuteroenzalutamide soft capsule is a first-class new drug developed by the company for the treatment of metastatic castration-resistant prostate cancer (mCRPC) [1] - The drug is a second-generation androgen receptor (AR) inhibitor and has received support from the National Major New Drug Creation Science and Technology Major Project [1]